Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Transl Oncol ; 26(7): 1779-1789, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38512450

ABSTRACT

OBJECTIVES: The S-REAL study aimed to assess the effectiveness of durvalumab as consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world cohort of patients with locally advanced, unresectable stage III non-small cell lung cancer (LA-NSCLC) included in a Spanish early access program (EAP). METHODS: In this multicentre, observational, retrospective study we analysed data from patients treated in 39 Spanish hospitals, who started intravenous durvalumab (10 mg/kg every 2 weeks) between September 2017 and December 2018. The primary endpoint was progression-free survival (PFS). Secondary endpoints included patient characterization and adverse events of special interest (AESI). RESULTS: A total of 244 patients were followed up for a median of 21.9 months [range 1.2-34.7]. Median duration of durvalumab was 45.5 weeks (11.4 months) [0-145]. Median PFS was 16.7 months (95% CI 12.2-25). No remarkable differences in PFS were observed between patients with programmed cell death-ligand 1 (PD-L1) expression ≥ 1% or < 1% (16.7 versus 15.6 months, respectively). However, PFS was higher in patients who had received prior concurrent CRT (cCRT) versus sequential CRT (sCRT) (20.6 versus 9.4 months). AESIs leading to durvalumab discontinuation were registered in 11.1% of patients. CONCLUSIONS: These results are in line with prior published evidence and confirm the benefits of durvalumab in the treatment of LA-NSCLC patients in a real-world setting. We also observed a lower incidence of important treatment-associated toxicities, such as pneumonitis, compared with the pivotal phase III PACIFIC clinical study.


Subject(s)
Antibodies, Monoclonal , Carcinoma, Non-Small-Cell Lung , Chemoradiotherapy , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/mortality , Male , Female , Lung Neoplasms/therapy , Lung Neoplasms/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Retrospective Studies , Aged , Middle Aged , Spain , Antibodies, Monoclonal/therapeutic use , Adult , Aged, 80 and over , Antineoplastic Agents, Immunological/therapeutic use , Neoplasm Staging , Progression-Free Survival , Consolidation Chemotherapy , B7-H1 Antigen/antagonists & inhibitors
2.
Anticancer Drugs ; 29(9): 821-826, 2018 10.
Article in English | MEDLINE | ID: mdl-30036190

ABSTRACT

The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on the management of liposomal and pegylated liposomal anthracyclines. The aim of this paper was to review the scientific literature on the extravasation of liposomal and pegylated liposomal anthracyclines and determine the clinical impact of this type of extravasation, focusing on dexrazoxane. The literature was searched using two databases: PubMed and Embase. Three searches were conducted, using liposomal anthracycline extravasation, pegylated liposomal anthracycline extravasation, and liposomal doxorubicin extravasation as keywords, respectively. Seven articles fulfilled the study eligibility criteria and included seventeen cases in humans. Extravasation occurred with three drugs: liposomal doxorubicin in nine (53%) patients, liposomal daunorubicin in four (23.5%) patients, and pegylated liposomal doxorubicin in four (23.5%) patients. General measures for extravasations were applied in all patients, but only three patients received dexrazoxane. All cases were completely resolved at 2-3 months, except for one patient, in whom dexrazoxane was not used. In animals, dexrazoxane decreased both the frequency of wounds produced by pegylated liposomal doxorubicin and their extent. The pharmacokinetic profiles of liposomal and pegylated liposomal anthracyclines differ from those of conventional anthracyclines, modifying their effectiveness and safety. General measures may be inadequate to heal areas affected by extravasation, which may require the administration of dexrazoxane. However, each case should be evaluated individually for the administration of dexrazoxane in off-label use until scientific evidence is available on its effectiveness and safety as an antidote for these formulations of anthracyclines.


Subject(s)
Anthracyclines/administration & dosage , Dexrazoxane/administration & dosage , Extravasation of Diagnostic and Therapeutic Materials/drug therapy , Animals , Anthracyclines/adverse effects , Anthracyclines/pharmacokinetics , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/adverse effects , Antibiotics, Antineoplastic/pharmacokinetics , Daunorubicin/administration & dosage , Daunorubicin/adverse effects , Daunorubicin/pharmacokinetics , Dexrazoxane/adverse effects , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Doxorubicin/analogs & derivatives , Doxorubicin/pharmacokinetics , Extravasation of Diagnostic and Therapeutic Materials/etiology , Humans , Liposomes , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Polyethylene Glycols/pharmacokinetics
3.
Rev Esp Enferm Dig ; 107(12): 732-9, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26671585

ABSTRACT

OBJECTIVE: The purpose of this study was to assess the resectability and effectiveness of repeat hepatectomy for relapsing liver metastases of colorectal origin in terms of morbidity, mortality, overall survival, and disease-free survival. METHODS: A retrospective study was performed on a prospective cohort of patients with colorectal liver metastases who underwent repeat surgery at Hospital Universitario San Cecilio, Granada (Spain), from March 2003 to June 2013. Primary outcome variables included survival and morbidity within 30 days post-surgery. RESULTS: A total of 147 patients with colorectal liver metastases underwent surgical excision during the study period; 61 patients had liver recurrence, and 34 of these received repeat surgery. The overall survival rate at 5 and 10 years for resected patients (n=27/34) was 48% and 48%. Mean hospital stay was 8.9 ± 3.5 days, morbidity was 9%, and mortality was 0%. CONCLUSION: Repeat liver resection for colorectal liver metastases is a safe, effective surgical procedure whose results are similar to those obtained after initial liver resection.


Subject(s)
Colorectal Neoplasms/pathology , Hepatectomy , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/secondary , Neoplasm Recurrence, Local/surgery , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Liver Neoplasms/mortality , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Reoperation , Retrospective Studies , Survival Analysis , Treatment Outcome
4.
Rev. esp. enferm. dig ; 107(12): 732-739, dic. 2015. tab, ilus, graf
Article in Spanish | IBECS | ID: ibc-146740

ABSTRACT

OBJETIVO: el objetivo de este estudio es evaluar la resecabilidad efectividad de las rehepatectomías en metástasis hepáticas de origen colorrectal recidivadas en términos de morbimortalidad, supervivencia global y libre de enfermedad. MÉTODOS: se realizó un estudio retrospectivo de una cohorte prospectiva de pacientes con metástasis hepáticas de origen colorrectal con cirugía de repetición en el Hospital Universitario San Cecilio de Granada de marzo de 2003 hasta junio de 2013. Las variables principales de resultado fueron la supervivencia y la morbilidad antes de los 30 días del postoperatorio. RESULTADOS: un total de 147 pacientes con metástasis hepáticas de origen colorrectal se sometieron a la extirpación quirúrgica durante el periodo de estudio; 61 pacientes presentaron una recidiva hepática de los cuales 34 se sometieron a una cirugía de repetición. La tasa global de supervivencia a 5 y 10 años para los pacientes resecados fue del 48 y el 48%. La estancia media hospitalaria fue de 8,9 ± 3,5 días, la morbilidad del 9% y la mortalidad del 0%. CONCLUSIÓN: las resecciones hepáticas repetidas para las metástasis hepáticas de origen colorrectal constituyen una operación segura y eficaz, con resultados similares a los obtenidos tras una primera resección hepática


OBJECTIVE: The purpose of this study was to assess the resectability and effectiveness of repeat hepatectomy for relapsing liver metastases of colorectal origin in terms of morbidity, mortality, overall survival, and disease-free survival. METHODS: A retrospective study was performed on a prospective cohort of patients with colorectal liver metastases who underwent repeat surgery at Hospital Universitario San Cecilio, Granada (Spain), from March 2003 to June 2013. Primary outcome variables included survival and morbidity within 30 days post-surgery. RESULTS: A total of 147 patients with colorectal liver metastases underwent surgical excision during the study period; 61 patients had liver recurrence, and 34 of these received repeat surgery. The overall survival rate at 5 and 10 years for resected patients (n=27/34) was 48% and 48%. Mean hospital stay was 8.9 ± 3.5 days, morbidity was 9%, and mortality was 0%. CONCLUSION: Repeat liver resection for colorectal liver metastases is a safe, effective surgical procedure whose results are similar to those obtained after initial liver resection


Subject(s)
Humans , Colorectal Neoplasms/pathology , Liver Neoplasms/surgery , Hepatectomy/statistics & numerical data , Neoplasm Metastasis , Neoplasm Recurrence, Local/epidemiology , Liver Neoplasms/secondary , Reoperation/statistics & numerical data , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...